Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HCV virological assessment.

Xavier Forns1, Josep Costa

  • 1Liver Unit, Hospital Clinic, IDIBAPS, Villarroel 170, 08036 Barcelona, Spain. xforns@clinic.ub.es

Journal of Hepatology
|December 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of drug-induced liver injury in the urban primary care setting.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

From targets to real world impact: a review of models of care for chronic HBV and HCV in Europe.

The Lancet regional health. Europe·2026
Same author

Early hepatitis B and delta virus kinetics in patients undergoing liver transplantation.

Scientific reports·2026
Same author

siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.

Journal of hepatology·2026
Same author

Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Clinical features and management for CDK4/6 inhibitor-DILI.

JHEP reports : innovation in hepatology·2026
Same journal

Moving Too Fast? A Meta-Analysis Calls for Caution on TNF Inhibitors as First-Line Therapy for Autoimmune Hepatitis.

Journal of hepatology·2026
Same journal

Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44<sup>+</sup>pDC crosstalk.

Journal of hepatology·2026
Same journal

Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration.

Journal of hepatology·2026
Same journal

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.

Journal of hepatology·2026
Same journal

Response to "Single-nucleus and spatial transcriptomic analyses reveal intra-tissue heterogeneity of PNPLA3".

Journal of hepatology·2026
Same journal

One-stop liquid biopsy: Can a single blood sample reveal the full spectrum of liver disease?

Journal of hepatology·2026
See all related articles

Virological assays for Hepatitis C Virus (HCV) infection are crucial for diagnosis and treatment. Special considerations are needed for co-infected patients due to unique characteristics impacting assay interpretation.

Area of Science:

  • Virology
  • Infectious Diseases
  • Immunology

Background:

  • Virological assessment of Hepatitis C Virus (HCV) infection is vital for diagnosis and therapeutic decisions.
  • Diagnostic assays include antibody detection, viral load quantification, and genotyping.
  • Co-infected patients (HCV and HIV) present unique challenges in assay interpretation due to immune status and higher viral loads.

Purpose of the Study:

  • To review the application and interpretation of virological assays in HCV mono-infected versus HCV/HIV co-infected patients.
  • To highlight differences in assay performance and utility in co-infected individuals.
  • To provide guidance on selecting appropriate assays for co-infected populations.

Main Methods:

  • Review of existing literature on HCV virological assays.

Related Experiment Videos

  • Comparison of assay sensitivity and specificity in mono-infected and co-infected cohorts.
  • Analysis of factors influencing assay interpretation in co-infected patients.

    • Main Results:

    • Last-generation anti-HCV antibody tests show similar sensitivity in both groups.
    • HCV-RNA testing is valuable for diagnosing liver disease in anti-HCV negative individuals.
    • Sequence analysis is preferred for HCV genotyping in co-infected patients due to lower sensitivity of serotyping assays.
    • Higher HCV-RNA concentrations in co-infected patients necessitate assays with a wide dynamic range for treatment monitoring.

    Conclusions:

    • Virological assay interpretation requires specific considerations in HCV/HIV co-infected patients.
    • Appropriate assay selection is critical for accurate diagnosis, monitoring, and guiding therapy in co-infected individuals.
    • Further research may be needed to optimize diagnostic and monitoring strategies for this population.